Jevtana

Type: Product

Name: Jevtana

First reported May 16 2013 - Updated May 16 2013 - 1 reports

FDA clears Bayer/ Algeta's prostate cancer radiotherapy

Approval for Xofigo comes three months ahead of scheduleThe US FDA has approved Bayer and Algeta's Xofigo for castration-resistant prostate cancer (CRPC) that has spread to the bone but no other organs.Xofigo (radium-223 dichloride) was approved three ... [Published PMLive - May 16 2013]

Entities: Algeta ASA, Bayer AG, Radiation Therapy

First reported May 14 2013 - Updated May 14 2013 - 1 reports

JEVTANA (Cabazitaxel) Kit [Sanofi-Aventis U.S. LLC]

Updated Date: May 7, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - May 14 2013]

Entities: Cabazitaxel, Jevtana, Sanofi-aventis US

First reported May 09 2013 - Updated May 09 2013 - 1 reports

JEVTANA (Cabazitaxel) Kit [Sanofi-Aventis U.S. LLC]

Updated Date: May 7, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - May 09 2013]

Entities: Cabazitaxel, Jevtana, Sanofi-aventis US

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Prostate Cancer: No Cost-Effective Way to Save Lives

All of the current treatment strategies for castration-resistant prostate cancer (CRPC) exceed the generally accepted criteria for cost-effectiveness, according to an analysis reported here.The least costly of the regimens exceeded the $100,000 threshold ... [Published Surgical Products - May 07 2013]

Entities: Prostate Cancer, leuprolide, Cabazitaxel, Denosumab

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Cabazitaxel: A guide to its use in hormone-refractory metastatic prostate cancer - Abstract

The taxane derivative cabazitaxel (Jevtana(®)) is approved in the USA and the EU for use in combination with prednisone for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing re ... [Published UroToday - May 06 2013]

Entities: Cabazitaxel, Metastatic, Prostate Cancer

First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

Is Docetaxel Still a Stalwart in Prostate Cancer?

Docetaxel (Taxotere) with prednisone holds firms as first-line chemotherapy in metastatic castration-resistant prostate cancer, but other treatment options are hot on its heels, including cabozantinib (Cometriq) and abiraterone (Zytiga). A review article ... [Published Consultant Live - Apr 19 2013]

Entities: docetaxel, Prostate Cancer, Cabazitaxel, Metastatic

First reported Mar 12 2013 - Updated Mar 13 2013 - 1 reports

Human medicines European Public Assessment Report (EPAR): Jevtana, cabazitaxel, Revision: 6, Authorised

[Published Pending EC decisions and European Public Assess ... - Mar 12 2013]

Entities: Cabazitaxel, Jevtana

Quotes

"All current treatment options exceeded the societal threshold for willingness to pay of $100,000," said Pollard. "However, the effectiveness of the current paradigm is likely to improve and costs are likely to reduce due to learning and competition that would potentially decrease the incremental cost-effectiveness ratio (ICER)."

Prostate Cancer: No Cost-Effective Way to Save Lives [Published Surgical Products - May 07 2013]

...By tracking the size and price of each montha'a "s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin."

HA, CPSS, EDGW, SNY, ASTM, UACL Are Seasonally Ripe To Go Down In the Next Five Weeks [Published TradingCharts.com - May 07 2013]

"The treatment paradigm will continue to change," said Pollard. "A better understanding of the quality-of-life outcomes will help to guide judicious use of available treatments."

Prostate Ca: No Cost-Effective Way to Save Lives (CME/CE) [Published MedPage Today - May 06 2013]

"The initiation of multiple investigator-sponsored Phase 2 trials, across tumor types, represents a significant inflection point in the creation of value for OGX-427 for which we currently retain all commercialization rights" said Scott Cormack

OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financ ... [Published WTNZ - May 02 2013]

More Content

sort by: Date \| Relevance
FDA clears Bayer/ Algeta's prostate cancer radi... [Published PMLive - May 16 2013]
Dendreon's Management Presents at Bank of Ameri... [Published Seeking Alpha - May 15 2013]
JEVTANA (Cabazitaxel) Kit [Sanofi-Aventis U.S. ... [Published DailyMed Drug Label Updates for the last seven ... - May 14 2013]
JEVTANA (Cabazitaxel) Kit [Sanofi-Aventis U.S. ... [Published DailyMed Drug Label Updates for the last seven ... - May 09 2013]
Prostate Cancer: No Cost-Effective Way to Save ... [Published Surgical Products - May 07 2013]
HA, CPSS, EDGW, SNY, ASTM, UACL Are Seasonally ... [Published TradingCharts.com - May 07 2013]
Physicians Expect Xtandi (Enzalutamide) to Beco... [Published PT Community - May 07 2013]
OncoGenex Loss Lower than Expected - Analyst Blog [Published Nasdaq - May 06 2013]
Prostate Ca: No Cost-Effective Way to Save Live... [Published MedPage Today - May 06 2013]
Cabazitaxel: A guide to its use in hormone-refr... [Published UroToday - May 06 2013]
OncoGenex Pharmaceuticals' CEO Discusses Q1 201... [Published Seeking Alpha - May 03 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published WTNZ - May 02 2013]
OncoGenex Pharmaceuticals Provides Clinical Dev... [Published Equities.com - May 02 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published Yahoo! Finance - May 02 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published Canada NewsWire - May 02 2013]
Is Docetaxel Still a Stalwart in Prostate Cancer? [Published Consultant Live - Apr 19 2013]
Research and Markets: Jevtana (Prostate Cancer)... [Published Business Wire Health News - Mar 20 2013]
According to Surveyed Oncologists in the EU5, Z... [Published PR Newswire: Entertainment & Media - Mar 18 2013]
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Mar 12 2013]
Men have more options in prostate cancer treatm... [Published Stevens Point Journal - Sep 30 2012]
Adapting to a New Era of Cancer Care [Published Pharmaceutical Executive - Aug 15 2012]